Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6406398 | 0.86 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6412773 | 0.83 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6290604 | 0.83 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6409670 | 0.77 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6407260 | 0.77 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6290660 | 0.77 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6412906 | 0.77 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6413069 | 0.75 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6407877 | 0.75 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6406296 | 0.74 | PDE5A (1.00) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6864253-B2 | Benzo[4,5]thieno[2,3-c]pyridine and Benzo[4,5]furo[2,3-c]pyridine Derivatives Useful as Inhibitors of Phosphodiesterase | ORTH-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1289985-B1 | BETA-CARBOLINE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE | ORTHO MCNEIL PHARM INC (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20030166641-A1 | Beta-carboline derivatives useful as inhibitors of phosphodiesterase | SUI ZHIHUA (US) | 2003-09-04 | — | — | US | disclosed |
| US-6492358-B2 | FOR TREATMENT OF SEXUAL DISORDERS, MALE ERECTILE DYSFUNCTION | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-12-10 | — | — | US | disclosed |
| US-20020010189-A1 | beta-carboline derivatives useful as inhibitors of phosphodiesterase | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010189-A1 | beta-carboline derivatives useful as inhibitors of phosphodiesterase | PDE3B, PDE5A, PDE3A | PDE5A 2/4885 |
| US-20030166641-A1 | Beta-carboline derivatives useful as inhibitors of phosphodiesterase | PDE3B, PDE5A, PDE3A | PDE5A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.